Korro Bio, Inc. (KRRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Henry Jiang

Everyone. Good morning. Thank you all for joining us today. My name is Henry Jiang. I’m with the banking team here at JPMorgan, and it’s my pleasure to be introducing Korro Bio today. Joining us on stage and presenting will be Ram Aiyar, President and CEO of Korro Bio. Just a quick note, we’ll have some time after the presentation for questions, so please wait until then. But without further ado, I’ll pass it over to you, Ram.

Ram Aiyar
CEO, President, Interim CFO, Principal Financial Officer & Director

Also, thank you for the JPMorgan Healthcare team for giving us the opportunity to present here today. It’s great to see this amazing crowd here. So thank you for being here. Really appreciate it. Hopefully, we’ll tell you a little bit about what we do at Korro.

Here are my customary forward-looking statements, you can always go to the SEC to find our most latest filings. So what do we do at Korro? At Korro, our vision is to develop transformative medicines for both rare as well as highly prevalent indications. And so we do that primarily by activating biological pathways. It’s a very hard thing to do. Most modalities are focused on knocking down proteins or knocking down certain areas. Gene therapy is the only one where you can add another protein or activate signals. In this case, we use a simple chemically modified oligonucleotide or RNA to go and effect the change, okay? So we do that to make a single base change from an adenosine to inosine by editing RNA, not touching DNA at all to really impact the protein structure